Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Retinoid-X receptor agonist promotes remyelination Next Article
Masitinib: a first-in-class TKI as treatment of progressive MS »
« Retinoid-X receptor agonist promotes remyelination Next Article
Masitinib: a first-in-class TKI as treatment of progressive MS »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles

November 8, 2019
Use of clinical registries in phase 4 of DMT
July 30, 2019
Clinical relevance of neurofilament light chain levels
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy